These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
259 related items for PubMed ID: 31237134
21. Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides. Ballantyne CM, Jones PH, Kelly MT, Setze CM, Lele A, Thakker KM, Stolzenbach JC. Cardiovasc Drugs Ther; 2011 Feb; 25(1):59-67. PubMed ID: 21416219 [Abstract] [Full Text] [Related]
22. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia. Maki KC, Bays HE, Dicklin MR, Johnson SL, Shabbout M. J Clin Lipidol; 2011 Feb; 5(6):483-92. PubMed ID: 22108152 [Abstract] [Full Text] [Related]
23. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, Shao M, Hu B, McErlean E, Nissen SE. JAMA; 2011 Nov 16; 306(19):2099-109. PubMed ID: 22089718 [Abstract] [Full Text] [Related]
24. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, Martineau P, Davignon J, CAP Investigators. Clin Ther; 2008 Dec 16; 30(12):2298-313. PubMed ID: 19167589 [Abstract] [Full Text] [Related]
25. A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia. Karlson BW, Palmer MK, Nicholls SJ, Lundman P, Barter PJ. Am J Cardiol; 2016 May 01; 117(9):1444-8. PubMed ID: 26969416 [Abstract] [Full Text] [Related]
26. [Efficacy and safety of various doses of hybutimibe monotherapy or in combination with atorvastatin for primary hypercholesterolemia: a multicenter, randomized, double-blind, double-dummy, parallel-controlled phase Ⅲ clinical trial]. Cai SY, Gu X, Liu PJ, Li RS, Jiang JJ, Zhao SP, Yao W, Jiang YN, Yin YH, Yu B, Yuan ZY, Wang JA. Zhonghua Xin Xue Guan Bing Za Zhi; 2023 Feb 24; 51(2):180-187. PubMed ID: 36789598 [Abstract] [Full Text] [Related]
27. Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial. Insull W, Ghali JK, Hassman DR, Y As JW, Gandhi SK, Miller E, SOLAR Study Group. Mayo Clin Proc; 2007 May 24; 82(5):543-50. PubMed ID: 17493418 [Abstract] [Full Text] [Related]
28. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group. McKenney JM, McCormick LS, Weiss S, Koren M, Kafonek S, Black DM. Am J Med; 1998 Feb 24; 104(2):137-43. PubMed ID: 9528731 [Abstract] [Full Text] [Related]
29. Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects. Roth EM, Bays HE, Forker AD, Maki KC, Carter R, Doyle RT, Stein EA. J Cardiovasc Pharmacol; 2009 Sep 24; 54(3):196-203. PubMed ID: 19597368 [Abstract] [Full Text] [Related]
30. A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study. Olsson AG, Eriksson M, Johnson O, Kjellström T, Lanke J, Larsen ML, Pedersen T, Tikkanen MJ, Wiklund O, 3T Study Investigators. Clin Ther; 2003 Jan 24; 25(1):119-38. PubMed ID: 12637115 [Abstract] [Full Text] [Related]
31. Short-Term Efficacy (at 12 Weeks) and Long-Term Safety (up to 52 Weeks) of Omega-3 Free Fatty Acids (AZD0585) for the Treatment of Japanese Patients With Dyslipidemia - A Randomized, Double-Blind, Placebo-Controlled, Phase III Study. Yokote K, Niwa K, Hakoda T, Oh F, Kajimoto Y, Fukui T, Kim H, Noda Y, Lundström T, Yajima T. Circ J; 2020 May 25; 84(6):994-1003. PubMed ID: 32281579 [Abstract] [Full Text] [Related]
32. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study. Wu CC, Sy R, Tanphaichitr V, Hin AT, Suyono S, Lee YT. J Formos Med Assoc; 2002 Jul 25; 101(7):478-87. PubMed ID: 12353340 [Abstract] [Full Text] [Related]
33. Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST). Davidson MH, Rosenson RS, Maki KC, Nicholls SJ, Ballantyne CM, Mazzone T, Carlson DM, Williams LA, Kelly MT, Camp HS, Lele A, Stolzenbach JC. Arterioscler Thromb Vasc Biol; 2014 Jun 25; 34(6):1298-306. PubMed ID: 24743431 [Abstract] [Full Text] [Related]
34. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels. Querton L, Buysschaert M, Hermans MP. J Clin Lipidol; 2012 Jun 25; 6(5):434-42. PubMed ID: 23009779 [Abstract] [Full Text] [Related]
35. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. Vallejo-Vaz AJ, Fayyad R, Boekholdt SM, Hovingh GK, Kastelein JJ, Melamed S, Barter P, Waters DD, Ray KK. Circulation; 2018 Aug 21; 138(8):770-781. PubMed ID: 29618599 [Abstract] [Full Text] [Related]
36. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S. Clin Ther; 2008 Jun 21; 30(6):1089-101. PubMed ID: 18640465 [Abstract] [Full Text] [Related]
37. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature. Ito MK. Atherosclerosis; 2015 Oct 21; 242(2):647-56. PubMed ID: 26296750 [Abstract] [Full Text] [Related]
38. A double-blind, double-dummy, randomized, placebo-controlled trial to evaluate the effect of statin therapy on triglyceride levels in Mexican hypertriglyceridemic patients. Talavera JO, Martinez G, Cervantes JL, Marin JA, Rodriguez-Briones I, Gonzalez JG, Ocampo R, Sanchez-Mijangos H, Bernal-Rosales LP, Polanco A. Curr Med Res Opin; 2013 Apr 21; 29(4):379-86. PubMed ID: 23323877 [Abstract] [Full Text] [Related]
39. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Maki KC, McKenney JM, Reeves MS, Lubin BC, Dicklin MR. Am J Cardiol; 2008 Aug 15; 102(4):429-33. PubMed ID: 18678300 [Abstract] [Full Text] [Related]
40. Efficacy and Tolerability of Pitavastatin Versus Pitavastatin/Fenofibrate in High-risk Korean Patients with Mixed Dyslipidemia: A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial. Ihm SH, Chung WB, Lee JM, Hwang BH, Yoo KD, Her SH, Song WH, Chae IH, Park TH, Kim JH, Jeon DW, Cho BR, Kang SH, Park SD, Lee JB, Woo JT, Lee BW, Han KA, Won KH, Kim HS, Yu JM, Chung CH, Kim HJ, Cho HC, Seung KB. Clin Ther; 2020 Oct 15; 42(10):2021-2035.e3. PubMed ID: 32891418 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]